Carrillo-Esper R, de la Torre-León T

Idioma: Español
Referencias bibliográficas: 27
Paginas: 380-387
Archivo PDF: 237.07 Kb.

RESUMEN

El eje hipotálamo-hipofisario-adrenal se activa en respuesta al estrés. La arginina-vasopresina es una hormona de estrés implicada en la respuesta hemodinámica y en la osmorregulación. La copeptina es un glucopéptido de 39 aminoácidos que incluye el segmento C-terminal de la arginina-vasopresina que se secreta conjuntamente con la arginina-vasopresina a partir del hipotálamo en respuesta al estrés. La copeptina es un biomarcador no específico de la respuesta al estrés. Se asocia directamente con la gravedad de la enfermedad, por lo que se ha propuesto como marcador pronóstico en diferentes escenarios clínicos, entre los que destacan: sepsis, neumonía, insuficiencia cardiaca, síndromes coronarios agudos, hemorragia subaracnoidea, evento vascular cerebral y otras enfermedades agudas. Las concentraciones de copeptina mejoran la información acerca del pronóstico, por lo que pueden guiar las intervenciones y optimizar el tratamiento de los pacientes. Esta revisión resume la evidencia actual relacionada con la copeptina como biomarcador pronóstico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. McEwen B. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007;87:873-904.

2. Tanoue A, Ito S, Honda K, Oshikawa S, et al. The vasopressin V1b receptor critically regulates hypothalamicpituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest 2004;113:302-309.

3. Christ M, Jaccard D, Bingisser R, Gencay MM, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: clusterrandomised, single-blinded intervention trial. Lancet 2004;363:600-607.

4. Land H, Schütz G, Schmale H, Richter D: Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature 1982;295:299- 303.

5. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005;26:2500-2504.

6. Singh G. The physiology and emerging roles of antidiuretic hormone. Int J Clin Pract 2002;56:777-782.

7. Barat C, Simpson L, Breslow E. Properties of human vasopressin precursor constructs: inefficient monomer folding in the absence of copeptin as a potential contributor to diabetes insipidus. Biochemistry 2004;43:8191-8203.

8. Christ C, Opal M. The role of biomarkers in the diagnosis and management of community-acquired pneumonia. Critical Care 2010;14:203-211.

9. Gallo-Payet N, Roussy J, Chagnon F, Roberge C, Lesur O. Hypothalamic-pituitary-adrenal axis and MODS in critical illness: special focus on arginine-vasopressin (AVP) and apelin (APL). J Organ Dysfunction 2008;4:216-229.

10. Morgenthaler NG, Muller B, Struck J, Bergmann A, et al. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007;28:219-226.

11. Muller B, Morgenthaler N, Stolz D, Schuetz P, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007;37:145-152.

12. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007;131:1058-1067.

13. Ahmed A, Aronow W, Fleg J. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J 2006;151:444-450.

14. Stoiser B, Mortl D, Hulsmann M, Berger R, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006;36:771-778.

15. Khan S, Dhillon O, O’Brien R, Struck J, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007;115:2103-2110.

16. Tang WH, Francis GS, Morrow DA, Newby LK, et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007;116:99-109.

17. Hoorn EJ, Halperin ML, Zietse R. Diagnostic approach to a patient with hyponatraemia: traditional versus physiology-based options. QJM 2005;98:529-540.

18. Meijer E, Bakker SJ, de Jong P, Homan van der Heide JJ, et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 2009;88:561-567.

19. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005;352:1884-1890.

20. Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 2003;17:471-503.

21. Joynt RJ, Feibel JH, Sladek CM. Antidiuretic hormone levels in stroke patients. Ann Neurol 1981;9:182-184.

22. Barreca T, Gandolfo C, Corsini G, Del Sette M, et al. Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients. Cerebrovasc Dis 2001;11:113-118.

23. Katan M, Fluri F, Morgenthaler N, Schuetz P, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009;66:799-808.

24. Isman F, Zulfikaroglu B, Isbilen B, Ozalp N, et al. Copeptin is a predictive biomarker of severity in acute pancreatitis. Am J Emerg Med 2013;15:1016-1020.

25. Saleem U, Khaleghi M, Morguenthaler, NG, Bergmann A, et al. Plasma carboxy-terminal provasopressin (Copeptin): A novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab 2009;94:2558-2564.

26. Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid hemorrhage grading scale. J Neurosurg 1998;68:985-986.

27. Fung C, De Marchis GM, Katan M, Seiler M, et al. Copeptin as a marker for severity and prognosis of aneurysmal subarachnoid hemorrhage. PLoS One 2013;8:e53191. doi: 10.1371.